Professional Summary
> Experience in Object Oriented Programming, design, development and
implementation of scalable and robust software systems using Java and
J2EE.
> Substantial knowledge in Core Java.
> Sound knowledge in web oriented software development using Servlets, JSP,
JDBC, JNDI, JMS, Hibernate, Struts, Spring, EJBs, and Web Services.
> Familiar with XML and related technologies like AJAX, DOM/SAX parsers,
HTML, JSTL, CSS and JavaScript.
> Good experience in Object Relational Mapping tools, Hibernate.
> Knowledge in Web services using SOAP, WSDL and frameworks such ad Axis.
> Experience in using WebLogic and Websphere.
> Good Experience with Eclipse, MyEclipse and RAD
> Proficiency in the development of Web applications using MVC frameworks
including Apache Struts and Spring MVC.
> Used Log4j for logging and debugging purposes and JUnit for testing.
> Strong experience in Unix/Linux environment and shell scripting.
Software/Technical Skills
Operating Systems Windows, UNIX, Linux
Languages Java, C, C++, SQL
Web Technologies HTML, JSP, Servlets, Struts, JUnit, UNIX Shell
scripting, JavaScript, AJAX, XML, XSD, Webservices,
Hibernate, Spring MVC
J2EE Technologies EJB, RMI, JNDI, JDBC, JMS
IDE Eclipse, MyEclipse, RAD
Design Patterns J2EE Design Patterns: Business Delegate, Service
Locator, DAO, Session Fa ade, MVC, Front Controller
Application Tomcat, BEA Web Logic Server
Servers
Databases Oracle, SQL
Protocols TCP/IP, HTTP, HTTPS
Query Tools SQL
Testing Tools JUnit
Build Tools Ant, Maven
Education
1999 - 2003 : Doctor of Philosophy (Chemistry), Bharathidasan University,
India
1996 - 1998: Master of Science (Chemistry) St.Joseph's College,
Tiruchirappalli, India
1993 - 1996: Bachelor in Science (Chemistry) St.Joseph's College,
Tiruchirappalli, India
Certification:
> Oracle Certified Professional Java SE 6 Programmer (score 85%) .
Nationwide Insurance, Columbus, OH
Jun. 2013 - July. 2013
Application Development Center
Java J2EE Developer
Overview: Nationwide is one of the largest insurance and financial services
companies in the world. It provides insurance, retirement, investments,
and other products to consumers in the US. The Application Development
Center (ADC) develops an application for policy agents, users and policy
holders to handle day-to-day policy activities.
My project was Beginning of the Day (BOD) that allows the policy agents to
update and retrieve the day-to-day policy activity from portal. Major part
of my work was code-analysis and fixing the defects. We used hibernate to
access IBM-DB2 data base.
Responsibilities:
. Used Struts MVC based framework to develop the Application
Architecture.
. Implemented DAO for data access using Hibernate.
. Code analysis and fixing the defects.
. Designed and developed stored procedures.
. Used Junit for unit testing the application.
. Used JavaScript for client side validation.
. Used Log4J for logging.
. Used Subversion as source/version control.
. Used WebSphere application server and RAD as IDE for developing,
deploying and testing the application.
Environment:
Java, WebSphere, RAD, JSP, CSS, Struts, Web services, XML, HTML,
JavaScript, Hibernate, DB2.
Intern, Idhasoft Inc. Atlanta, GA
Sept. 2012 - Dec. 2013
During the internship, I obtained training on Employee Portal Management,
Manager Portal and Personal Banking System using Java/J2EE technologies.
Research (Non-IT) Experience
2009 - 2010 : Postdoctoral Researcher, Southern Research Institute, Drug
Discovery
Division, Birmingham, AL.
2006 - 2008 : Postdoctoral Research Fellow, Department of Chemistry,
University of
Louisville, Louisville, KY.
2004 - 2006 : Postdoctoral Research Fellow, Department of Biochemistry,
University
of Iowa, IA.
2002 - 2003 : Senior Research Fellow (Council of Scientific and
Industrial Research,
Government of India)
1999 - 2001 : Research Scholar, Bharathidasan University,
Tiruchirappalli, India.
Brief description of the current work at Southern Research Institute,
Birmingham
Structure and Function of Proline-rich Tyrosine Kinase (PYK2): Pyk2 is a
non-receptor tyrosine kinase (PTKs) implicated in integrin-dependent
tyrosine-phosphorylation and engage in focal adhesion where it colocalizes
with several other proteins to transduce information from cells to the
extracellular matrix and vice versa. Increased expression of PYK2 has been
observed in several human tumors and that presents this kinase a potential
molecular therapeutic target for cancer. Also it is considered a potential
drug target for osteoporosis treatment. Pyk2 composed of number of
functional domains including the NH2-terminal FERM domain, a central
catalytic kinase domain and a carboxyl-terminal focal adhesion targeting
(FAT) domain.
To date, the regulatory FERM domain of Pyk2 was the only functional domain
which lacked structural information, though the homology model of the FERM
domain of Pyk2 has recently been reported. In order to understand the
structural basis for the regulation of Pyk2, the data were collected to
3.2 from a crystal of Pyk2 Ferm domain and the manuscript is in
preparation. In pursuit of studying the full length Pyk2 structure,
recently we collected several data sets ranging from 1.7 - 2.0 from
crystals containing Ferm and kinase domains of Pyk2. Studying the structure
of this enzyme would reveal the functional role that Pyk2 plays in cellular
biology and facilitate in manipulating this drug target for therapeutic
purpose.
Summary of the work done at Department of Chemistry, University of
Louisville
Study on the structure and function of self-aminoacylating ribonucleic
acids (RNA) using x-ray crystallography: RNA can act as biocatalysts and
should, in principle, be able to catalyze most biological reactions
currently catalyzed by proteins. Our aim in studying the structure of RNA
was
. To unravel the functions of a catalytic RNA at the atomic level
. To understand how ribozymes (RNA) recognize substrates and perform
catalytic functions
. How can we modify these functions through structure-based RNA design
To address these, I had crystallized and optimized growth conditions in two
different crystal lattices of a particular RNA that has 66 nucleotides. The
crystallographic data has been collected both on a diffractometer (a
rotating anode x-ray source) as well as at the synchrotron facility
(Advanced Photon Source-Argonne National Lab., Chicago).
Summary of the work done at Department of Biochemistry, The University of
Iowa
Study on high resolution structures of Alcohol Dehydrogenases (ADH): ADH
plays an important physiological function in Mammals, where it facilitates
the reversible oxidation of alcohols into aldehydes and ketones with
Nicotinamide Adenine Dinucleotide (NAD) as the coenzyme. In yeast and
bacteria, ADH plays a similar role in fermentation, where it catalyzes
acetaldehyde into ethanol. These structural studies of ADHs are important
in developing therapeutic drugs for acute alcoholism and drug dependency in
patients.
Towards this effort I had worked on three different projects.
. Solved complex structures of Liver Alcohol Dehydrogenase with selected
lead compounds that would potentially treat poisoning by methanol and
ethylene glycol.
. Determined the structures of Liver ADH apo-enzyme and complexes with
ligands that bind to the catalytic zinc ion.
. Determined the Yeast (Saccharomyces cerevisiae) ADH, the enzyme of
choice for the production of ethanol from corn.
Summary of the Research work done at School of Chemistry, Bharathidasan
University
Crystallographic Studies of some complexes of Sulphoxine and Trimethoprim:
Sulphoxine and Trimethoprim are antiamoebic and antibacterial drugs
respectively.
. Studied the metal binding modes of sulphoxine.
. Studied trimethoprim-carboxylate interactions.
Obtained some remarkable structural motifs, in the form of H-bonded
chains, sheets and networks. These motifs are potentially important for
molecular recognition in the fields of crystal engineering/supramolecular
chemistry. Interestingly, some of the H-bonded interactions discovered in
my studies have actually been observed in protein-nucleic acid interactions
thereby proving that these interactions could be considered as a model for
drug-receptor recognition (the aminopyrimidine moiety of the drug forms H-
bonds with the carboxylate anion of the receptor molecule).